New York, May 31, 2026, 15:02 EDT
Pfizer Inc. (PFE.N) heads into Monday’s open with investors facing a heavier cancer-drug news tape than its stock price showed last week, after fresh oncology data at the American Society of Clinical Oncology meeting and a China partnership worth up to $10.5 billion.
The timing matters. U.S. trading was shut Sunday, and the previous week was shortened by the Memorial Day closure on Monday; the NYSE’s core session runs from 9:30 a.m. to 4 p.m. ET. That leaves Monday as the first full market test for most of the weekend ASCO data.
Pfizer closed Friday at $26.18, up 0.15%, and finished the holiday-shortened week about 1.1% above its May 22 close of $25.90. The S&P 500 ETF gained 0.24% Friday, while the Health Care Select Sector SPDR ETF fell 0.89%; among large drugmakers, Eli Lilly lost 1.93%, Merck fell 0.98% and Bristol Myers Squibb rose 0.49%.
The stock move was small. The issue is not.
Pfizer is trying to convince investors it has a growth story after the pandemic-era surge in COVID products faded and as patent expirations pressure older drugs. Reuters reported earlier this month that the company expects stronger growth after 2028 from obesity drugs in development, cancer medicines, Vyndamax patent protection and a favorable European court ruling on COVID vaccine purchases.
The most immediate readout came Sunday from Braftovi in a genetic subtype of metastatic colorectal cancer. Pfizer said the regimen nearly doubled progression-free survival — the time patients live without the cancer worsening — to 15.2 months from 8.3 months in the comparator arm, and cut the risk of death by 44%. Scott Kopetz of MD Anderson, co-principal investigator of the trial, said the results “strengthen confidence” in treatment for this patient group. Pfizer
A day earlier, Pfizer said Talzenna plus Xtandi reduced the risk of radiographic progression or death — disease worsening seen on scans, or death — by 52% in metastatic prostate cancer with certain DNA-repair gene changes. Neeraj Agarwal of Huntsman Cancer Institute, the trial’s global lead investigator, called the result “durable disease control,” while Pfizer said the overall survival data were still interim. Pfizer
Pfizer also released seven-year Lorbrena data in ALK-positive advanced non-small cell lung cancer, saying 55% of patients remained alive without disease progression at seven years. Tony Shu-Kam Mok of the Chinese University of Hong Kong called the outcomes “remarkable” and a “fundamental shift” for expectations in that disease. Pfizer
Away from the conference floor, Pfizer and Innovent Biologics announced a 12-program oncology collaboration covering antibody-drug conjugates, or ADCs — cancer drugs designed to carry a cell-killing payload to tumors — and multi-specific antibodies. Innovent will get $650 million upfront and could receive up to $9.85 billion in milestone payments; Jeff Legos, Pfizer’s chief oncology officer, said the companies aim to “move faster, go further.” Pfizer
Investors have heard this kind of pitch before. In Pfizer’s first-quarter release, CEO Albert Bourla said the company’s pipeline was advancing in oncology and obesity, and CFO David Denton pointed to 22% operational revenue growth from launched and acquired products; revenue was $14.45 billion and Pfizer reaffirmed 2026 revenue guidance of $59.5 billion to $62.5 billion.
Analysts have still wanted more proof. J.P. Morgan analyst Chris Schott told Reuters investors need more clinical data and lower risk around pipeline programs before sentiment improves, while RBC Capital’s Trung Huynh described Pfizer as a “catalyst story, not an earnings story.” Reuters
The week ahead keeps oncology in focus. Pfizer’s ASCO schedule includes Monday presentations in breast cancer and gynecological cancers, and a Tuesday oral presentation on tucatinib as maintenance therapy in HER2-positive metastatic breast cancer. Not every abstract moves a stock, but after several days of data, investors have enough to reprice the pipeline debate if they choose to.
But the downside is plain. Some of the new data are interim or early, several programs still need regulators and commercial uptake, and the Innovent assets are early-stage medicines that must clear Phase 1 trials before Pfizer leads global development. The company’s own disclosure on the Innovent deal flagged closing risk, uncertain clinical endpoints, regulatory questions and the chance that expected benefits are not realized.
For now, Pfizer’s share price is not trading like a breakout. The weekend gave investors more substance to test — not a clean answer. Monday’s open will show whether that is enough.
